| . | NSTEMI . | STEMI . | P value . |
|---|---|---|---|
| n = 203 . | n = 217 . | ||
| Age (years) | 65 ± 11 | 62 ± 10 | 0.004 |
| BMI (kg/m2) | 27.8 ± 5.0 | 27.7 ± 4.1 | 0.828 |
| Female sex | 44 (21.7%) | 36 (16.6%) | 0.185 |
| Smoking status | 0.221 | ||
| Current | 64 (32.0%) | 59 (27.2%) | |
| Previous | 65 (32.5%) | 63 (29.0%) | |
| Hypertension | 109 (53.7%) | 113 (52.1%) | 0.739 |
| Diabetes | 37 (18.2%) | 24 (11.1%) | 0.037 |
| Hypercholesterolemia | 84 (41.6%) | 69 (31.8%) | 0.038 |
| Family history of pre-mature atherosclerosis | 77 (38.7%) | 51 (23.5%) | <0.001 |
| Previous MI | 36 (17.7%) | 27 (12.4%) | 0.129 |
| Previous PCI | 39 (19.2%) | 23 (10.6%) | 0.013 |
| Previous CVA | 5 (2.5%) | 3 (1.4%) | 0.491 |
| History of carotid artery disease | 7 (3.4%) | 6 (2.8%) | 0.686 |
| History of PAD | 9 (4.4%) | 8 (3.7%) | 0.698 |
| Total cholesterol (mmol/L) | 4.9 ± 1.3 | 5.1 ± 1.4 | 0.139 |
| LDL-cholesterol (mmol/L) | 2.9 ± 1.2 | 3.2 ± 1.2 | 0.010 |
| Triglycerides (mmol/L) | 2.1 ± 1.5 | 1.8 ± 1.4 | 0.037 |
| eGFR (mL/min) | 75.4 ± 18.8 | 83.9 ± 18.6 | <0.001 |
| CRP (mg/L) | 6.8 ± 16.9 | 7.0 ± 27.3 | 0.933 |
| Leukocytes (×109/L) | 8.9 ± 2.8 | 10.5 ± 3.4 | <0.001 |
| Lipid lowering therapy at presentation | 67 (33.0%) | 41 (18.9%) | <0.001 |
| Infarct related artery | |||
| LM | 3 (1.5%) | 2 (0.9%) | 0.676 |
| LAD | 83 (40.9%) | 84 (38.7%) | 0.649 |
| Cx | 66 (32.5%) | 42 (19.4%) | 0.002 |
| RCA | 59 (29.1%) | 98 (45.2%) | <0.001 |
| NC lesion assessment | |||
| Immediate | 114 (56.2%) | 42 (19.4%) | <0.001 |
| Staged | 89 (43.8%) | 175 (80.6%) | <0.001 |
| Time to staged procedure (days) | 16 ± 14 | 17 ± 16 | 0.598 |
| Number of NC lesions | 1.19 ± 0.44 | 1.16 ± 0.39 | 0.450 |
| NC lesion distribution | |||
| LM | 3 (1.5%) | 1 (0.5%) | 0.357 |
| LAD | 86 (42.4%) | 89 (41.0%) | 0.779 |
| Cx | 69 (34.0%) | 85 (39.2%) | 0.271 |
| RCA | 63 (31.0%) | 59 (27.2%) | 0.386 |
| Targeted NC FFR | 0.89 ± 0.05 | 0.89 ± 0.05 | 0.256 |
| . | NSTEMI . | STEMI . | P value . |
|---|---|---|---|
| n = 203 . | n = 217 . | ||
| Age (years) | 65 ± 11 | 62 ± 10 | 0.004 |
| BMI (kg/m2) | 27.8 ± 5.0 | 27.7 ± 4.1 | 0.828 |
| Female sex | 44 (21.7%) | 36 (16.6%) | 0.185 |
| Smoking status | 0.221 | ||
| Current | 64 (32.0%) | 59 (27.2%) | |
| Previous | 65 (32.5%) | 63 (29.0%) | |
| Hypertension | 109 (53.7%) | 113 (52.1%) | 0.739 |
| Diabetes | 37 (18.2%) | 24 (11.1%) | 0.037 |
| Hypercholesterolemia | 84 (41.6%) | 69 (31.8%) | 0.038 |
| Family history of pre-mature atherosclerosis | 77 (38.7%) | 51 (23.5%) | <0.001 |
| Previous MI | 36 (17.7%) | 27 (12.4%) | 0.129 |
| Previous PCI | 39 (19.2%) | 23 (10.6%) | 0.013 |
| Previous CVA | 5 (2.5%) | 3 (1.4%) | 0.491 |
| History of carotid artery disease | 7 (3.4%) | 6 (2.8%) | 0.686 |
| History of PAD | 9 (4.4%) | 8 (3.7%) | 0.698 |
| Total cholesterol (mmol/L) | 4.9 ± 1.3 | 5.1 ± 1.4 | 0.139 |
| LDL-cholesterol (mmol/L) | 2.9 ± 1.2 | 3.2 ± 1.2 | 0.010 |
| Triglycerides (mmol/L) | 2.1 ± 1.5 | 1.8 ± 1.4 | 0.037 |
| eGFR (mL/min) | 75.4 ± 18.8 | 83.9 ± 18.6 | <0.001 |
| CRP (mg/L) | 6.8 ± 16.9 | 7.0 ± 27.3 | 0.933 |
| Leukocytes (×109/L) | 8.9 ± 2.8 | 10.5 ± 3.4 | <0.001 |
| Lipid lowering therapy at presentation | 67 (33.0%) | 41 (18.9%) | <0.001 |
| Infarct related artery | |||
| LM | 3 (1.5%) | 2 (0.9%) | 0.676 |
| LAD | 83 (40.9%) | 84 (38.7%) | 0.649 |
| Cx | 66 (32.5%) | 42 (19.4%) | 0.002 |
| RCA | 59 (29.1%) | 98 (45.2%) | <0.001 |
| NC lesion assessment | |||
| Immediate | 114 (56.2%) | 42 (19.4%) | <0.001 |
| Staged | 89 (43.8%) | 175 (80.6%) | <0.001 |
| Time to staged procedure (days) | 16 ± 14 | 17 ± 16 | 0.598 |
| Number of NC lesions | 1.19 ± 0.44 | 1.16 ± 0.39 | 0.450 |
| NC lesion distribution | |||
| LM | 3 (1.5%) | 1 (0.5%) | 0.357 |
| LAD | 86 (42.4%) | 89 (41.0%) | 0.779 |
| Cx | 69 (34.0%) | 85 (39.2%) | 0.271 |
| RCA | 63 (31.0%) | 59 (27.2%) | 0.386 |
| Targeted NC FFR | 0.89 ± 0.05 | 0.89 ± 0.05 | 0.256 |
BMI, body mass index; CRP, c-reactive protein; CVA, cerebrovascular accident; Cx, circumflex artery; eGFR, estimated glomerular filtration rate; FFR, fractional flow reserve; LAD, left anterior descending artery; LDL, low-density lipoprotein; LM, left main coronary artery; MI, myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; RCA, right coronary artery; STEMI, ST-segment elevation myocardial infarction
| . | NSTEMI . | STEMI . | P value . |
|---|---|---|---|
| n = 203 . | n = 217 . | ||
| Age (years) | 65 ± 11 | 62 ± 10 | 0.004 |
| BMI (kg/m2) | 27.8 ± 5.0 | 27.7 ± 4.1 | 0.828 |
| Female sex | 44 (21.7%) | 36 (16.6%) | 0.185 |
| Smoking status | 0.221 | ||
| Current | 64 (32.0%) | 59 (27.2%) | |
| Previous | 65 (32.5%) | 63 (29.0%) | |
| Hypertension | 109 (53.7%) | 113 (52.1%) | 0.739 |
| Diabetes | 37 (18.2%) | 24 (11.1%) | 0.037 |
| Hypercholesterolemia | 84 (41.6%) | 69 (31.8%) | 0.038 |
| Family history of pre-mature atherosclerosis | 77 (38.7%) | 51 (23.5%) | <0.001 |
| Previous MI | 36 (17.7%) | 27 (12.4%) | 0.129 |
| Previous PCI | 39 (19.2%) | 23 (10.6%) | 0.013 |
| Previous CVA | 5 (2.5%) | 3 (1.4%) | 0.491 |
| History of carotid artery disease | 7 (3.4%) | 6 (2.8%) | 0.686 |
| History of PAD | 9 (4.4%) | 8 (3.7%) | 0.698 |
| Total cholesterol (mmol/L) | 4.9 ± 1.3 | 5.1 ± 1.4 | 0.139 |
| LDL-cholesterol (mmol/L) | 2.9 ± 1.2 | 3.2 ± 1.2 | 0.010 |
| Triglycerides (mmol/L) | 2.1 ± 1.5 | 1.8 ± 1.4 | 0.037 |
| eGFR (mL/min) | 75.4 ± 18.8 | 83.9 ± 18.6 | <0.001 |
| CRP (mg/L) | 6.8 ± 16.9 | 7.0 ± 27.3 | 0.933 |
| Leukocytes (×109/L) | 8.9 ± 2.8 | 10.5 ± 3.4 | <0.001 |
| Lipid lowering therapy at presentation | 67 (33.0%) | 41 (18.9%) | <0.001 |
| Infarct related artery | |||
| LM | 3 (1.5%) | 2 (0.9%) | 0.676 |
| LAD | 83 (40.9%) | 84 (38.7%) | 0.649 |
| Cx | 66 (32.5%) | 42 (19.4%) | 0.002 |
| RCA | 59 (29.1%) | 98 (45.2%) | <0.001 |
| NC lesion assessment | |||
| Immediate | 114 (56.2%) | 42 (19.4%) | <0.001 |
| Staged | 89 (43.8%) | 175 (80.6%) | <0.001 |
| Time to staged procedure (days) | 16 ± 14 | 17 ± 16 | 0.598 |
| Number of NC lesions | 1.19 ± 0.44 | 1.16 ± 0.39 | 0.450 |
| NC lesion distribution | |||
| LM | 3 (1.5%) | 1 (0.5%) | 0.357 |
| LAD | 86 (42.4%) | 89 (41.0%) | 0.779 |
| Cx | 69 (34.0%) | 85 (39.2%) | 0.271 |
| RCA | 63 (31.0%) | 59 (27.2%) | 0.386 |
| Targeted NC FFR | 0.89 ± 0.05 | 0.89 ± 0.05 | 0.256 |
| . | NSTEMI . | STEMI . | P value . |
|---|---|---|---|
| n = 203 . | n = 217 . | ||
| Age (years) | 65 ± 11 | 62 ± 10 | 0.004 |
| BMI (kg/m2) | 27.8 ± 5.0 | 27.7 ± 4.1 | 0.828 |
| Female sex | 44 (21.7%) | 36 (16.6%) | 0.185 |
| Smoking status | 0.221 | ||
| Current | 64 (32.0%) | 59 (27.2%) | |
| Previous | 65 (32.5%) | 63 (29.0%) | |
| Hypertension | 109 (53.7%) | 113 (52.1%) | 0.739 |
| Diabetes | 37 (18.2%) | 24 (11.1%) | 0.037 |
| Hypercholesterolemia | 84 (41.6%) | 69 (31.8%) | 0.038 |
| Family history of pre-mature atherosclerosis | 77 (38.7%) | 51 (23.5%) | <0.001 |
| Previous MI | 36 (17.7%) | 27 (12.4%) | 0.129 |
| Previous PCI | 39 (19.2%) | 23 (10.6%) | 0.013 |
| Previous CVA | 5 (2.5%) | 3 (1.4%) | 0.491 |
| History of carotid artery disease | 7 (3.4%) | 6 (2.8%) | 0.686 |
| History of PAD | 9 (4.4%) | 8 (3.7%) | 0.698 |
| Total cholesterol (mmol/L) | 4.9 ± 1.3 | 5.1 ± 1.4 | 0.139 |
| LDL-cholesterol (mmol/L) | 2.9 ± 1.2 | 3.2 ± 1.2 | 0.010 |
| Triglycerides (mmol/L) | 2.1 ± 1.5 | 1.8 ± 1.4 | 0.037 |
| eGFR (mL/min) | 75.4 ± 18.8 | 83.9 ± 18.6 | <0.001 |
| CRP (mg/L) | 6.8 ± 16.9 | 7.0 ± 27.3 | 0.933 |
| Leukocytes (×109/L) | 8.9 ± 2.8 | 10.5 ± 3.4 | <0.001 |
| Lipid lowering therapy at presentation | 67 (33.0%) | 41 (18.9%) | <0.001 |
| Infarct related artery | |||
| LM | 3 (1.5%) | 2 (0.9%) | 0.676 |
| LAD | 83 (40.9%) | 84 (38.7%) | 0.649 |
| Cx | 66 (32.5%) | 42 (19.4%) | 0.002 |
| RCA | 59 (29.1%) | 98 (45.2%) | <0.001 |
| NC lesion assessment | |||
| Immediate | 114 (56.2%) | 42 (19.4%) | <0.001 |
| Staged | 89 (43.8%) | 175 (80.6%) | <0.001 |
| Time to staged procedure (days) | 16 ± 14 | 17 ± 16 | 0.598 |
| Number of NC lesions | 1.19 ± 0.44 | 1.16 ± 0.39 | 0.450 |
| NC lesion distribution | |||
| LM | 3 (1.5%) | 1 (0.5%) | 0.357 |
| LAD | 86 (42.4%) | 89 (41.0%) | 0.779 |
| Cx | 69 (34.0%) | 85 (39.2%) | 0.271 |
| RCA | 63 (31.0%) | 59 (27.2%) | 0.386 |
| Targeted NC FFR | 0.89 ± 0.05 | 0.89 ± 0.05 | 0.256 |
BMI, body mass index; CRP, c-reactive protein; CVA, cerebrovascular accident; Cx, circumflex artery; eGFR, estimated glomerular filtration rate; FFR, fractional flow reserve; LAD, left anterior descending artery; LDL, low-density lipoprotein; LM, left main coronary artery; MI, myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; RCA, right coronary artery; STEMI, ST-segment elevation myocardial infarction
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
